Free Trial

Regeneron Pharmaceuticals Top Holdings and 13F Report (2026)

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals NASDAQ: REGN has filed 13-F forms with the SEC as an investor. Regeneron Pharmaceuticals is itself a publicly traded company. Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. For more information on Regeneron Pharmaceuticals stock, visit the Regeneron Pharmaceuticals stock profile here.

Investment Activity

  • Regeneron Pharmaceuticals has $179.63 million in total holdings as of September 30, 2026.
  • Regeneron Pharmaceuticals owns shares of 3 different stocks, but just 2 companies or ETFs make up 80% of its holdings.
  • This quarter, Regeneron Pharmaceuticals has purchased 3 new stocks and bought additional shares in 0 stocks.
  • Regeneron Pharmaceuticals sold shares of 0 stocks and completely divested from 0 stocks this quarter.

Largest Holdings

Parabilis Medicines, Inc.
$134,541,645
Adicet Bio, Inc.
$432,049

Sector Allocation Over Time

Map of 500 Largest Holdings ofRegeneron Pharmaceuticals

 
 
Selling
 
 
Neutral
 
 
Buying
Issuer NameHoldings ValueApproximate Purchase/SaleChange in SharesShares Held% of PortfolioSector
Parabilis Medicines, Inc.
$134,541,6450.0%4,166,66674.9%Common Stock
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$44,658,1200.0%3,702,99524.9%Healthcare
Adicet Bio, Inc.
$432,0490.0%60,5110.2%Common Stock

Showing largest 100 holdings. View all holdings.
SEC Filings and Trading Data